Oppenheimer Maintains A Balanced Outlook on ACADIA Pharmaceuticals Inc. (ACAD) For 2026
TheFly reported on February 6 that Oppenheimer raised its price target on ACAD to $23 from $21 and maintained a Perform rating on the shares.
Acadia Pharmaceuticals Inc (ACAD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 42,896,690 | $1,145,770,590 | 6.71% | |
| 2. | Point72 Asset Management Steve Cohen | 3,377,311 | $90,207,977 | +128% | 0.1% |
| 3. | Palo Alto Investors William Leland Edwards | 2,484,031 | $66,348,468 | +1% | 9.24% |
| 4. | Braidwell LP Alex Karnal | 2,032,021 | $54,275,281 | -15% | 1.74% |
| 5. | Renaissance Technologies Jim Simons | 1,532,596 | $40,935,639 | +6% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.65 | 259,109 | $6,646,145.85 | 39,317,673 | 2023-05-24 | Filing | |
| $25.65 | 24,113 | $618,498.45 | 3,610,443 | 2023-05-24 | Filing | |
| $25.51 | 28,878 | $736,787.52 | 39,058,564 | 2023-05-24 | Filing | |
| $25.51 | 2,688 | $68,581.09 | 3,586,330 | 2023-05-24 | Filing | |
| $25.27 | 218,171 | $5,513,682.96 | 39,029,686 | 2023-05-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.38 | 6,950 | $162,491.00 | 7,609 | 2026-02-09 | Filing | |
| $23.69 | 10,262 | $243,113.96 | 53,338 | 2025-11-18 | Filing | |
| $23.69 | 4,084 | $96,753.64 | 25,058 | 2025-11-18 | Filing | |
| $22.37 | 30,000 | $670,983.00 | 4,041 | 2025-11-10 | Filing | |
| $23.65 | 3,498 | $82,727.70 | 43,447 | 2025-09-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,755,452 | $554,378,124 | 0.01% | |
| 2. | 15,153,957 | $404,762,192 | 0.01% | |
| 3. | 7,910,733 | $211,295,678 | 0.01% | |
| 4. | 7,144,524 | $190,830,236 | 1.91% | |
| 5. | 3,239,451 | $86,539,034 | 0.01% |
News See All
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to ACADIA Pharmaceuticals' Third Quarter 2025 Financial Results Conference Call.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company that focuses on therapies for central nervous system disorders and rare diseases.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Gerald, and I'll be your host for today.
Hedge Fund Resource Center Billionaire Hedge Funds
